REGULATory T-Cell Inhibition With Basiliximab (Simulect) During Recovery From Therapeutic Temozolomide-induced Lymphopenia During Antitumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme

Trial Profile

REGULATory T-Cell Inhibition With Basiliximab (Simulect) During Recovery From Therapeutic Temozolomide-induced Lymphopenia During Antitumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Apr 2018

At a glance

  • Drugs Basiliximab (Primary) ; Cancer vaccine-pp65 (Primary) ; Autolymphocyte therapy; Temozolomide
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Acronyms REGULATe
  • Most Recent Events

    • 05 Apr 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
    • 05 Apr 2018 Planned primary completion date changed from 1 May 2018 to 1 May 2019.
    • 05 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top